Analysis

Latest

Shoeshine

The second wave for NZ’s medicinal cannabis industry

ANALYSIS: Investors have lost millions and companies have collapsed, but medicinal cannabis players still see a bright future.

Fiona Rotherham Tue, 07 Apr 2026

General Business

Medicinal cannabis firm Helius in voluntary administration

General Business

Noteholders seize control as Cannasouth tips into receivership

Primary Industries

Green Leaf-owned Cannabis Clinic pulls out of merger with Helius

Shoeshine

Winners and losers in NZ’s medicinal cannabis market

Investment

Listed medicinal cannabis firm Greenfern in receivership

Hunter’s Corner

The real meaning of energy security

ANALYSIS: If a $1b subsidy buys an LNG terminal, what’s it worth to reduce our reliance on imports?

Tim Hunter Fri, 20 Mar 2026

Edwards on Politics

The Treasury’s optimistic economic view of the Iran conflict

ANALYSIS: It might base its view on US Vice-President JD Vance’s assurance that President Trump isn’t as dumb as previous presidents.

Brent Edwards Thu, 19 Mar 2026

Underarm

New report puts ‘Robodebt’ scandal to bed, but smell lingers

ANALYSIS: Australia’s new National Anti-Corruption Commission releases long-awaited report on ‘Robodebt’ scandal that takes no action and raises questions about the Commission’s effectiveness.

Lachlan Colquhoun Wed, 18 Mar 2026

Margin Call

SaaSacre – buying opportunity or great value destroyer?

ANALYSIS: The risk is not near-term collapse; it’s long-run erosion in pricing power and premium economics.

James Cameron Tue, 17 Mar 2026

Shoeshine

An ugly solution to an age-old problem

ANALYSIS: A revamped offer from an unlisted property fund seeks to raise capital from new investors to help pay for the potential exits for older ones.